Literature DB >> 19494795

Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.

Sunita Babbar1, Jean-Francois Marier, Mohamad-Samer Mouksassi, Martin Beliveau, Geertrui F Vanhove, Sanjay Chanda, Keith Bley.   

Abstract

Capsaicin, a pungent compound in chili peppers, is a highly selective agonist for the transient receptor potential vanilloid 1 receptor expressed in nociceptive sensory nerves. A high-concentration (640 microg/cm2) capsaicin patch, designated NGX-4010, is in clinical evaluation for the management of peripheral neuropathic pain. To determine systemic capsaicin exposure after single 60- or 90-minute NGX-4010 applications, plasma samples were collected from 173 patients with postherpetic neuralgia (PHN), painful human immunodeficiency virus-associated neuropathy (HIV-AN), and painful diabetic neuropathy (PDN). The percentages of patients with quantifiable levels of capsaicin at any time point were 31% for PHN (30 of 96), 7% for HIV-AN (3 of 44), and 3% for PDN (1 of 33). The maximum plasma concentration observed in any patient was 17.8 ng/mL. Due to the limited number of quantifiable levels, a population analysis was performed to characterize the pharmacokinetics (PK) of capsaicin. Plasma concentrations were fitted adequately using a 1-compartment model with first-order absorption and linear elimination. Capsaicin levels declined very rapidly, with a mean population elimination half-life of 1.64 hours. Mean area under the curve and C max values after a 60-minute application were 7.42 ng x h/mL and 1.86 ng/mL, respectively. Only a few correlations between calculated PK parameters and patient characteristics were observed. Duration and area of application of the patch were detected as significant covariates explaining the PK of capsaicin. Ninety-minute applications of NGX-4010 resulted in capsaicin area under the curve and Cmax values approximately 1.78- and 2.15-fold higher than those observed in patients treated for 60 minutes. Treatment on the feet (patients with HIV-AN and PDN) produced far lower systemic exposure than treatment on the trunk (patients with PHN). Finally, larger treatment areas were associated with statistically higher Vc/F values. The low systemic exposure and very rapid elimination half-life of capsaicin after NGX-4010 administration are unlikely to result in systemic effects and support the overall safety profile of this investigational cutaneous patch.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494795     DOI: 10.1097/FTD.0b013e3181a8b200

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  32 in total

1.  Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.

Authors:  Martin R Farlow; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 2.  Transient receptor potential channels in pain and inflammation: therapeutic opportunities.

Authors:  Mark A Schumacher
Journal:  Pain Pract       Date:  2010-03-02       Impact factor: 3.183

3.  A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain.

Authors:  Ganesan Baranidharan; Sangeeta Das; Arun Bhaskar
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

4.  Capsaicin-induced activation of ERK1/2 and its involvement in GAP-43 expression and CGRP depletion in organotypically cultured DRG neurons.

Authors:  Yunfeng Li; Guixiang Liu; Hao Li; Youzheng Xu; Hong Zhang; Zhen Liu
Journal:  Cell Mol Neurobiol       Date:  2013-02-21       Impact factor: 5.046

5.  Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers.

Authors:  Hee Youn Choi; Yo Han Kim; Donghyun Hong; Seong Su Kim; Kyun-Seop Bae; Hyeong-Seok Lim
Journal:  Eur J Clin Pharmacol       Date:  2015-05-28       Impact factor: 2.953

Review 6.  Unravelling the mystery of capsaicin: a tool to understand and treat pain.

Authors:  Jessica O'Neill; Christina Brock; Anne Estrup Olesen; Trine Andresen; Matias Nilsson; Anthony H Dickenson
Journal:  Pharmacol Rev       Date:  2012-10       Impact factor: 25.468

7.  Reactive intermediates produced from the metabolism of the vanilloid ring of capsaicinoids by p450 enzymes.

Authors:  Christopher A Reilly; Fred Henion; Tim S Bugni; Manivannan Ethirajan; Chris Stockmann; Kartick C Pramanik; Sanjay K Srivastava; Garold S Yost
Journal:  Chem Res Toxicol       Date:  2012-11-06       Impact factor: 3.739

Review 8.  Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

9.  Oxidant-based anticancer activity of a novel synthetic analogue of capsaicin, capsaicin epoxide.

Authors:  Anna Lewinska; Pawel Chochrek; Karolina Smolag; Ewa Rawska; Maciej Wnuk
Journal:  Redox Rep       Date:  2014-11-08       Impact factor: 4.412

10.  Preparation and Evaluation of PLGA-Coated Capsaicin Magnetic Nanoparticles.

Authors:  Mrudhula Baskaran; Padmamalini Baskaran; Navamoney Arulsamy; Baskaran Thyagarajan
Journal:  Pharm Res       Date:  2017-03-21       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.